Highlights from ACG2025
Focus on Ulcerative Colitis
DAY 3: New Therapeutics Under Development for IBD, with Novel Mechanisms of Action
Vipul Jairath, MBChB, DPhil, MRCP, from Western University in Ontario Canada, reported on the 28-week safety and efficacy of icotrokinra (formerly JNJ-2113), an oral therapy that selectively blocks IL-23 receptor activation, in ulcerative colitis (UC).
October 30, 2025
Read more
DAY 3: Comparative Studies of Inflammatory Bowel Disease Advanced Therapeutics
Several sessions, presentations, and posters described studies aimed at comparing the safety and efficacy of various advanced therapies available for inflammatory bowel disease (IBD), to help guide therapeutic selection. In a bonus session, Benjamin J. Click, MD, MS, described “buzzwords” that come to mind when thinking about the safety of the various classes of advanced IBD therapies
October 30, 2025
Read more
DAY 3: Efficacy and Safety of Biologics Targeting IL-12 and IL-23 in Inflammatory Bowel Disease
Jessica R. Allegretti, MD, MPH, FACG, from Brigham and Women’s Hospital and Harvard Medical School, presented week 48 efficacy and safety results from the phase 3 ASTRO study of subcutaneous guselkumab induction and maintenance therapy for ulcerative colitis (UC).
October 30, 2025
Read more
DAY 3: Recent Guideline Updates for IBD Clinical Care
Edward L. Barnes, MD, MPH, FACG, from University of North Carolina at Chapel Hill School of Medicine, reviewed the 2025 updates for Ulcerative Colitis (UC) management. He noted that since the last guidelines were published, the number of treatment options has increased, making management of UC highly complex.
October 30, 2025
Read moreMore Summaries
DAY 1: Monitoring Strategies in the Treatment of Inflammatory Bowel Disease
Jill K Gaidos, MD, FACG, from Yale School of Medicine, described a treat-to-target paradigm for initiating IBD therapy, based on the STRIDE-II treatment goals for IBD (Turner et al, 2021). These goals move through a series of short- to long-term targets, starting with symptomatic response and remission, decrease in calprotectin, and endoscopic evidence of healing with normalization of quality of life without disability.
October 28, 2025
Read more
DAY 1: Nationwide Analyses of Infection Burden, Risk Factors, and Outcomes Among Patients with IBD
Carol Singh, MBBS, from Dayanand Medical College and Hospital, shared results from a nationwide analysis of the impact of infections on outcomes in patients with ulcerative colitis (UC). The analysis included data on 826,945 patients with a diagnosis of UC in the National Inpatient Sample from 2016 to 2022; of which 36.2% developed infections. The most frequent infections were urinary tract infection (9.2%), hospital-acquired pneumonia (7.0%), and Clostridioides difficile infection (CDI; 6.2%).
October 28, 2025
Read more
DAY 1: The Role of the Gut Microbiome in IBD and the Therapeutic Potential of FMT
Kusalik Boppana, MBBS, from Kasturba Medical College of Manipal, conducted a systematic review of the literature to assess the use of gut microbiome dysbiosis as a diagnostic marker of early IBD. The analysis included 20 studies of 2,713 individuals with IBD and 1,976 healthy controls; 17 studies reported significantly reduced microbiome alpha diversity, and 12 studies reported differing beta diversity between those with early IBD (prior to symptoms) and controls.
October 28, 2025
Read more
DAY 1: The Potential of Advanced Combination Therapy to Improve Inflammatory Bowel Disease
In a bonus session, Bruce E. Sands, MD, MD, FACG, from Icahn School of Medicine at Mount Sinai, presented on the role of combination therapy in IBD. He noted that the field has reached a therapeutic ceiling with monotherapy (Raine & Danese, 2022), achieving at most 50% clinical and endoscopic remission rates. Combination therapy, along with earlier diagnosis and better monitoring, can help improve individual patient outcomes.
Oct 28, 2025
Read more
DAY 2: Disparities in IBD Care
Several posters reported research highlighting disparities in inflammatory bowel disease (IBD) prevalence, treatment, and outcomes across various healthcare settings. Aaron Tabibzadeh, MD, from New York University Langone Health, described the findings from qualitative focus group discussions with 23 adult patients with Crohn’s disease (CD) or ulcerative colitis (UC) receiving care in a safety-net healthcare setting and private academic IBD center in New York.
October 29, 2025
Read more
DAY 2: Applications of Artificial Intelligence in IBD Care
The scientific sessions showcased research on various applications of artificial intelligence (AI) in inflammatory bowel disease (IBD) clinical care, from analyzing patient care to improving endoscopic diagnostic accuracy. Nazmus Khan, BSc(Hons), MBChB, from McMaster University, compared the performance of four large language models (LLMs) in answering 46 IBD-related clinical questions from the American Gastroenterological Association (AGA) Digestive Diseases Self-Education Program.
October 29, 2025
Read more
DAY 2: The Future of IBD Clinical Practice
In her Presidential Address, Amy S. Oxentenko, MD, FACG, emphasized the need for new approaches in GI clinical practice that will ensure high-quality patient care into the future. Several presentations and papers focused on this topic. Corey A. Siegel, MD, MS, from Dartmouth Hitchcock Medical Center, delivered the Berk Lecture, “Redesigning the Delivery of IBD Care for the Future.” He identified five major concerns in the GI field that need to be addressed.
October 29, 2025
Read more
DAY 2: GLP-1 Receptor Agonists and IBD Outcomes
A few posters described the results of large nationwide retrospective analyses that consistently found a benefit of GLP-1 receptor agonist use on outcomes in patients with inflammatory bowel disease (IBD). Aun Muhammad, MD, from University of Mississippi Medical Center, conducted a retrospective cohort study using data from the TriNetX database.
October 29, 2025
Read more
DAY 2: JAK Inhibitors and S1P Receptor Modulators
The scientific sessions featured numerous presentations and posters reporting on the growing number of advanced therapeutics for inflammatory bowel disease (IBD); below are a few posters that focused on small molecule JAK inhibitors and S1P receptor modulators. Isabel Lopera, MD, from the Mayo Clinic, performed a retrospective review of 19 patients 16 years of age and older who were admitted for acute severe ulcerative colitis (UC) between 2023 and 2025 and treated with the JAK inhibitor upadacitinib.
October 29, 2025
Read more
© 2025 Wolters Kluwer. All right reserved.